30 Day Trial

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Product / Company Performance

Medtronic Posts FY1Q17 Revenue -

ORTHOWORLD estimates Medtronic's (MDT) FY1Q17 revenue of US $721.0MM, -5.4% vs. FY1Q16. Quarter ended 7/29/16; growth is as-reported.

ORTHOWORLD estimates spine and orthobiologic segment sales and growth on an as-reported basis, as follows, for FY1Q17. 

  • Spine $598.0MM, -6.0%
  • Orthobiologics $123.0MM, -2.4%


Per earnings call notes, MDT's Core Spine (hardware) revenue overall fell in low-single-digits, though U.S. growth was driven by new product launches. 

MDT reported U.S. Infuse sales growth in high-single-digits, with pricing stable, while international sales of IndustOs continued to be affected by a shipping hold in Europe. 

Further, the growth of spine products + spine imaging/navigation equipment, combined, hit high-single-digit growth in the U.S.

Received 2-level FDA Premarket Approval for Prestige LP

Received FDA 510(k) clearance to market the CD Horizon® Fenestrated Screw Set, indicated for treatment of advanced stage tumors in the thoracic and lumbar spine

Launched the Pivox™ Oblique Lateral Spinal System with Lateral Plate for OLIF25™ and Divergence-L™ Anterior/Oblique Lumbar Fusion System for OLIF51™.

Preparing to introduce Mazor X with Mazor Robotics at the 2016 NASS meeting

Sources: Medtronic, plc; ORTHOWORLD Inc.

This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.